These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 29422356

  • 1. Will 68Ga PSMA-radioligands be the only choice for nuclear medicine in prostate cancer in the near future? A clinical update.
    Cuccurullo V, di Stasio GD, Evangelista L, Ciarmiello A, Mansi L.
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(2):103-109. PubMed ID: 29422356
    [Abstract] [Full Text] [Related]

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 3. 68Ga-PSMA PET/CT in prostate cancer.
    García Garzón JR, de Arcocha Torres M, Delgado-Bolton R, Ceci F, Alvarez Ruiz S, Orcajo Rincón J, Caresia Aróztegui AP, García Velloso MJ, García Vicente AM, Oncology Task Force of Spanish Society of Nuclear Medicine and Molecular Imaging.
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(2):130-138. PubMed ID: 28941866
    [Abstract] [Full Text] [Related]

  • 4. Correlation between molecular tumor volume evaluated with 68Ga-PSMA PET/CT and prostatic specific antigen levels.
    Medina-Ornelas Sevastián S, García-Pérez Francisco O, Hernández-Pedro Norma Y, Arellano-Zarate Angélica E, Abúndiz-López Blanca L.
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(4):223-228. PubMed ID: 29454548
    [Abstract] [Full Text] [Related]

  • 5. Comparison of 68Ga-PSMA-11 PET/CT with 11C-acetate PET/CT in re-staging of prostate cancer relapse.
    Regula N, Kostaras V, Johansson S, Trampal C, Lindström E, Lubberink M, Velikyan I, Sörensen J.
    Sci Rep; 2020 Mar 19; 10(1):4993. PubMed ID: 32193430
    [Abstract] [Full Text] [Related]

  • 6. 68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.
    von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G.
    Eur Urol Focus; 2018 Sep 19; 4(5):686-693. PubMed ID: 28753806
    [Abstract] [Full Text] [Related]

  • 7. Is there a utility of adding skeletal imaging to 68-Ga-prostate-specific membrane antigen-PET/computed tomography in initial staging of patients with high-risk prostate cancer?
    Raju S, Sharma A, Patel C, Sahoo R, Das CJ, Kumar S, Sharma A, Kumar R.
    Nucl Med Commun; 2020 Nov 19; 41(11):1183-1188. PubMed ID: 32796451
    [Abstract] [Full Text] [Related]

  • 8. [PET/CT with (11)C-choline and (18)F-FDG in patients with elevated PSA after radical treatment of a prostate cancer].
    García JR, Soler M, Blanch MA, Ramírez I, Riera E, Lozano P, Pérez X, Delgado E, Carrio I, Lomeña F.
    Rev Esp Med Nucl; 2009 Nov 19; 28(3):95-100. PubMed ID: 19558948
    [Abstract] [Full Text] [Related]

  • 9. Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT.
    Schwenck J, Rempp H, Reischl G, Kruck S, Stenzl A, Nikolaou K, Pfannenberg C, la Fougère C.
    Eur J Nucl Med Mol Imaging; 2017 Jan 19; 44(1):92-101. PubMed ID: 27557844
    [Abstract] [Full Text] [Related]

  • 10. Value of post-therapy 177Lu-PSMA images for accurate interpretation of therapy response with 68Ga-PSMA PET/CT.
    Tuncel M, Telli T.
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018 Jan 19; 37(2):114-117. PubMed ID: 28750750
    [Abstract] [Full Text] [Related]

  • 11. 68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy.
    Ceci F, Castellucci P, Graziani T, Farolfi A, Fonti C, Lodi F, Fanti S.
    Eur J Nucl Med Mol Imaging; 2019 Jan 19; 46(1):31-39. PubMed ID: 30350010
    [Abstract] [Full Text] [Related]

  • 12. Diagnostic utility and therapeutic impact of PET/CT [18F]F-Fluoromethylcholine -Choline in the biochemical recurrence of prostate cancer.
    Sánchez N, Valduvieco I, Ribal MJ, Campos F, Casas F, Nicolau C, Salvador R, Mellado B, Jorcano S, Fuster D, Paredes P.
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020 Jan 19; 39(5):284-291. PubMed ID: 32467000
    [Abstract] [Full Text] [Related]

  • 13. Whole-Body Integrated [68Ga]PSMA-11-PET/MR Imaging in Patients with Recurrent Prostate Cancer: Comparison with Whole-Body PET/CT as the Standard of Reference.
    Guberina N, Hetkamp P, Ruebben H, Fendler W, Grueneisen J, Suntharalingam S, Kirchner J, Puellen L, Harke N, Radtke JP, Umutlu L, Hadaschik BA, Herrmann K, Forsting M, Wetter A.
    Mol Imaging Biol; 2020 Jun 19; 22(3):788-796. PubMed ID: 31482413
    [Abstract] [Full Text] [Related]

  • 14. (11)C-choline PET/CT and multiparametric MRI in patients with biochemical relapse of prostate cancer.
    Garcia JR, Romera N, Cozar M, Soler M, Moragas M, Escobar M.
    Actas Urol Esp; 2015 May 19; 39(4):259-63. PubMed ID: 25454265
    [Abstract] [Full Text] [Related]

  • 15. The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels.
    Kabasakal L, Demirci E, Nematyazar J, Akyel R, Razavi B, Ocak M, Aygun A, Obek C, Kural AR.
    Nucl Med Commun; 2017 Feb 19; 38(2):149-155. PubMed ID: 27893589
    [Abstract] [Full Text] [Related]

  • 16. Improving Diagnosis of Primary Prostate Cancer With Combined 68Ga-Prostate-Specific Membrane Antigen-HBED-CC Simultaneous PET and Multiparametric MRI and Clinical Parameters.
    Jena A, Taneja R, Taneja S, Singh A, Kumar V, Agarwal A, Subramanian N.
    AJR Am J Roentgenol; 2018 Dec 19; 211(6):1246-1253. PubMed ID: 30300002
    [Abstract] [Full Text] [Related]

  • 17. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
    Evangelista L, Briganti A, Fanti S, Joniau S, Reske S, Schiavina R, Stief C, Thalmann GN, Picchio M.
    Eur Urol; 2016 Jul 19; 70(1):161-175. PubMed ID: 26850970
    [Abstract] [Full Text] [Related]

  • 18. Potential Impact of 68Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer.
    Calais J, Kishan AU, Cao M, Fendler WP, Eiber M, Herrmann K, Ceci F, Reiter RE, Rettig MB, Hegde JV, Shaverdian N, King CR, Steinberg ML, Czernin J, Nickols NG.
    J Nucl Med; 2018 Nov 19; 59(11):1714-1721. PubMed ID: 29653978
    [Abstract] [Full Text] [Related]

  • 19. Role of 18F-Choline PET/CT in guiding biopsy in patients with risen PSA levels and previous negative biopsy for prostate cancer.
    Jiménez Londoño GA, García Vicente AM, Amo-Salas M, Fúnez Mayorga F, López Guerrero MA, Talavera Rubio MP, Gutierrez Martin P, González García B, de la Torre Pérez JA, Soriano Castrejón ÁM.
    Rev Esp Med Nucl Imagen Mol; 2017 Nov 19; 36(4):241-246. PubMed ID: 28330596
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.